MITAKY develops Japanese Autologous Adipose Stem Cell Therapy and immune cell therapies to treat conditions such as stroke, dementia, and knee pain by utilizing the patient's own cells to promote tissue regeneration and enhance immune response. The company also offers technology transfer services in regenerative medicine and robotics, facilitating the adoption of advanced Japanese technologies in global markets.
Funding
Funding not disclosed
Founders
Product
Problem
Many patients lack access to advanced regenerative medicine and immunotherapy treatments, particularly those leveraging autologous cell therapies, due to geographical limitations and the complexity of technology transfer. Furthermore, the adoption of cutting-edge Japanese medical technologies in global markets faces hurdles related to specialized knowledge and infrastructure requirements.
Solution
MITAKY facilitates access to Japanese autologous adipose stem cell therapy and immune cell therapies for conditions like stroke, dementia, knee pain, and various cancers. By leveraging a network of accredited medical centers in Japan, MITAKY enables patients to utilize their own cells for tissue regeneration and enhanced immune response. Additionally, the company offers technology transfer services, providing the know-how, skills, and innovations necessary for organizations to adopt advanced Japanese regenerative medicine and robotics technologies, including GMP lab setup and cell culturing techniques.
Target Audience
The primary target audience includes patients seeking advanced regenerative medicine and immunotherapy treatments, as well as organizations (both private and governmental) looking to adopt and implement cutting-edge Japanese medical technologies.
Features
- Facilitation of Japanese Autologous Adipose Tissue-Derived Stem Cell (ADSC) Therapy, involving stem cell extraction, processing in certified CPCs, and re-infusion for tissue regeneration.
- Access to Japanese Autologous Immune Cell Therapy for Cancer, utilizing patient's own immune cells (T-cells and NK cells) to combat various cancers.
- Technology transfer services for regenerative medical technologies (stem cell and immune cell cultivations), robotics, AI, renewable energy, biotechnology, nanotechnology, and environmental technologies.
- Support for setting up GMP laboratories, cell culturing, quality control, and patient counseling for regenerative medicine applications.
- Facilitation of high-quality medical and healthcare tourism support services in Japan.